Teva/GSK settle Relafen litigation
Executive Summary
All patent litigation between Teva and GSK regarding generics of Relafen (nabumetone) has been settled, Teva says April 30. Teva entered generic nabumetone market in August 2001 with 500 mg and 750 mg tablets following successful Boston federal court challenge of GSK patent (1"The Pink Sheet" Aug. 20, 2001, p. 14)...
You may also be interested in...
Teva Purinethol (correction)
Purinethol (6-mercaptopurine) is a Teva product; it was misidentified as a GlaxoSmithKline product in a recent story in "The Pink Sheet" (Oct. 30, p. 33). Teva received rights to Purinethol July 1 as part of its patent settlement with GSK regarding Relafen (nabumetone) generics (1"The Pink Sheet" May 5, 2003, In Brief)...
Teva Purinethol (correction)
In a story on Purinethol (6-mercaptopurine) labeling, "The Pink Sheet" referred to the leukemia drug as a GlaxoSmithKline product ("The Pink Sheet" July 21, 2003, p. 33). Teva received rights to Purinethol July 1 as part of its patent settlement with GSK regarding generics of Relafen (nabumetone) (1"The Pink Sheet" May 5, 2003, In Brief)...
Teva Launching Generic Relafen After Court Rules GSK Patent Invalid
Teva is "immediately" launching generic nabumetone following an Aug. 14 court decision upholding its patent challenge to GlaxoSmithKline's Relafen.